Trusted Resources: News & Meetings
Latest announcements and gatherings
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)
JCR Pharmaceuticals Co., Ltd. announced today that European Medicines Agency (EMA) has granted orphan drug designation to JR-171, an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome). JR-171 is a blood-brain-barrier (BBB)-penetrating form recombinant α-L-iduronidase that was developed using JCR’s proprietary J-Brain Cargo® BBB technology.
JR-171 received the orphan drug designation from the US Food Drug Administration (FDA) in February 2021. Currently JR-171 is undergoing a global Phase 1/2 clinical trial and the first patient in Japan was dosed in October, 2020 and in Brazil in March, 2021. The trial is also scheduled for enrolling patients in the US. The summary of this study is registered on clinicaltrials.gov.
BookmarkRelated Content
-
Long-Term Effect of Hematopoietic Cell Transplantation on Systemic Inflammation in Patients With Mucopolysaccharidos...Mucopolysaccharidoses (MPS) are devastat...
-
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
-
Mucopolysaccharidosis Conditions Explainedhttps://www.youtube.com/watch?v=EmSJ_hGE...
-
Enzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation SaysThe Cure Sanfilippo Foundation is encour...
-
Mucopolysaccharidoses Diagnosis in the Era of Enzyme Replacement Therapy in EgyptUndegraded glycosaminoglycans (GAGs) ind...
-
Open-Label Phase 1/2 Study of Vestronidase Alfa for Mucopolysaccharidosis VIIVestronidase alfa is an enzyme replaceme...
Powered by
